Biotech · Public company · San Diego, CA, US
Fate Therapeutics Inc
Ticker FATE · SEC CIK 0001434316
Track this companyFree. Adds Fate Therapeutics Inc to your Dealase workspace and tells you when its record changes.
Clinical trials217 recruiting or active
Pipeline programs73From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline73
- Control ArmPhase 2 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- FT819Phase 2 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
- FT839Phase 2 · ANCA-Associated Vasculitis (AAV)ClinicalTrials.gov · fetched Nov 12, 2026
- ProHema-CBPhase 2 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- ProTmunePhase 2 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- Untreated CBPhase 2 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- AvelumabPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- AvelumabPhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 1 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)ClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 1 · Relapsed/Refractory B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 1 · HER2 Positive Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 1 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)ClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Relapsed/Refractory B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- DaratumumabPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DaratumumabPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- ElotuzumabPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FATE-NK100Phase 1 · HER2 Positive Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Relapsed/Refractory B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)ClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- FT500Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- FT516Phase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FT516Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- FT522Phase 1 · Relapsed/Refractory B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- FT536Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- FT538Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FT538Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- FT576 (Allogenic CAR NK cells with BCMA expression)Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- FT596Phase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- FT819Phase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- FT819Phase 1 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)ClinicalTrials.gov · fetched Nov 12, 2026
- FT825Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- FT836Phase 1 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- IL-2Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IL-2Phase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- IL-2Phase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- IL-2Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Monoclonal antibody - Dose EscalationPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- Monoclonal antibody - Dose ExpansionPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ObinutuzumabPhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- ObinutuzumabPhase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 1 · Lymphoma, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 1 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 1 · Relapsed/Refractory B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 1 · HER2 Positive Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 1 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Allogeneic natural killer (NK) cellAdvanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Genetically engineered NK cellsHematological MalignancyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials21
- FT839 in Autoimmune DiseasesPHASE1_PHASE2 · RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07800871 · fetched Nov 12, 2026
- A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisPHASE2 · RECRUITING · started Jul 27, 2026ClinicalTrials.gov NCT07570862 · fetched Nov 12, 2026
- First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 AstrocytomaPHASE1 · RECRUITING · started Apr 23, 2026ClinicalTrials.gov NCT07560865 · fetched Nov 12, 2026
- FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsPHASE1 · RECRUITING · started Nov 4, 2025ClinicalTrials.gov NCT07216105 · fetched Nov 12, 2026
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseasePHASE1 · RECRUITING · started Mar 28, 2024ClinicalTrials.gov NCT06308978 · fetched Nov 12, 2026
- FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid TumorsPHASE1 · RECRUITING · started Jan 5, 2024ClinicalTrials.gov NCT06241456 · fetched Nov 12, 2026
- FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)PHASE1 · COMPLETED · started Nov 16, 2023ClinicalTrials.gov NCT05950334 · fetched Nov 12, 2026
- FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsPHASE1 · TERMINATED · started May 31, 2022ClinicalTrials.gov NCT05395052 · fetched Nov 12, 2026
- FT576 in Subjects With Multiple MyelomaPHASE1 · COMPLETED · started Nov 10, 2021ClinicalTrials.gov NCT05182073 · fetched Nov 12, 2026
- FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsPHASE1 · TERMINATED · started Oct 15, 2021ClinicalTrials.gov NCT05069935 · fetched Nov 12, 2026
- FT819 in Subjects With B-cell MalignanciesPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 12, 2021ClinicalTrials.gov NCT04629729 · fetched Nov 12, 2026
- FT538 in Subjects With Advanced Hematologic MalignanciesPHASE1 · TERMINATED · started Oct 17, 2020ClinicalTrials.gov NCT04614636 · fetched Nov 12, 2026
- FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsPHASE1 · TERMINATED · started Sep 7, 2020ClinicalTrials.gov NCT04551885 · fetched Nov 12, 2026
- FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesPHASE1 · TERMINATED · started Mar 19, 2020ClinicalTrials.gov NCT04245722 · fetched Nov 12, 2026
- FT516 in Subjects With Advanced Hematologic MalignanciesPHASE1 · TERMINATED · started Oct 4, 2019ClinicalTrials.gov NCT04023071 · fetched Nov 12, 2026
- Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular ImmunotherapyTERMINATED · started Oct 4, 2019ClinicalTrials.gov NCT04093622 · fetched Nov 12, 2026
- Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyTERMINATED · started Jun 11, 2019ClinicalTrials.gov NCT04106167 · fetched Nov 12, 2026
- FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsPHASE1 · COMPLETED · started Feb 15, 2019ClinicalTrials.gov NCT03841110 · fetched Nov 12, 2026
- FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsPHASE1 · COMPLETED · started Jan 18, 2018ClinicalTrials.gov NCT03319459 · fetched Nov 12, 2026
- Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesPHASE1_PHASE2 · COMPLETED · started Dec 20, 2016ClinicalTrials.gov NCT02743351 · fetched Nov 12, 2026
- The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.PHASE2 · TERMINATED · started Jul 1, 2012ClinicalTrials.gov NCT01627314 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026